
Avoid the heavily margined short in the unnamed biotech: the clinical-data catalyst creates substantial squeeze risk, and the allegations in the transcript are unverified. The mentions of SAVA, IONQ, and CAPR provide no actionable thesis. Treat an NVDA earnings bet as speculative; no outlook or trade plan is provided.

By @shkreliplanet